Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.

@article{King2011RobenacoxibIT,
  title={Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.},
  author={J N King and Jean Pierre Arnaud and E I Goldenthal and Philippe Gruet and Martin Jung and Wolfgang Seewald and Peter D Lees},
  journal={Journal of veterinary pharmacology and therapeutics},
  year={2011},
  volume={34 3},
  pages={298-311}
}
The safety of robenacoxib, a nonsteroidal anti-inflammatory drug with high selectivity for inhibition of the cyclooxygenase (COX)-2 isoform of COX, was investigated in the dog in two randomized, placebo-controlled, parallel group studies. Robenacoxib was administered orally once daily to healthy young beagle dogs at 0 (placebo), 10, 20 and 40 mg/kg for 1… CONTINUE READING